Janumet

Janumet. It is a fixed-dose combination medication used for the treatment of type 2 diabetes mellitus, containing two active pharmaceutical ingredients: sitagliptin and metformin. This dual mechanism targets both insulin deficiency and insulin resistance, key pathophysiological defects in the disease. It is typically prescribed when treatment with metformin alone does not provide adequate glycemic control.

Medical uses

Janumet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not for the treatment of type 1 diabetes or diabetic ketoacidosis. Clinical trials, such as those presented at the American Diabetes Association Scientific Sessions, have demonstrated its efficacy in lowering hemoglobin A1c levels. The combination is often used when monotherapy with metformin hydrochloride, the first-line agent recommended by the American Association of Clinical Endocrinology, proves insufficient. It may be used concomitantly with other antidiabetic agents, including sulfonylureas or insulin, under the guidance of an endocrinologist.

Adverse effects

Common adverse reactions are often related to the gastrointestinal effects of metformin and include diarrhea, nausea, vomiting, and flatulence. A serious but rare risk associated with metformin is lactic acidosis, a medical emergency. Postmarketing surveillance by the U.S. Food and Drug Administration has also reported potential adverse events like acute pancreatitis and severe joint pain. Hypoglycemia is more common when Janumet is used with other glucose-lowering drugs like insulin glargine. Allergic reactions, such as angioedema and Stevens-Johnson syndrome, have been documented in case reports published in journals like *The Lancet*.

Pharmacology

Sitagliptin is a dipeptidyl peptidase-4 inhibitor that works by inhibiting the DPP-4 enzyme, thereby increasing levels of active incretin hormones like glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon release from alpha cells. Metformin, a biguanide, primarily reduces hepatic gluconeogenesis and improves insulin sensitivity in peripheral tissues like muscle and adipose tissue. The pharmacokinetics show that sitagliptin is primarily excreted renally, while metformin undergoes renal elimination, necessitating caution in patients with renal impairment.

History

Sitagliptin, discovered by scientists at Merck & Co., was approved by the U.S. Food and Drug Administration in 2006 under the brand name Januvia. The fixed-dose combination with metformin was subsequently developed and approved as Janumet in 2007. This development followed the clinical success of metformin, which originated from the study of Galega officinalis and was popularized by researchers like Jean Sterne. The combination's approval was based on pivotal studies submitted to regulatory bodies like the European Medicines Agency. The extended-release formulation, Janumet XR, received approval later, offering once-daily dosing.

Society and culture

Janumet is a widely prescribed medication, with its sales contributing significantly to the portfolio of Merck & Co.. It has been the subject of direct-to-consumer advertising campaigns in the United States. The drug's cost and access have been debated within healthcare systems like the National Health Service in the United Kingdom. It is on the World Health Organization Model List of Essential Medicines in its individual component forms. The medication has been discussed in popular media, including health segments on CNN, and is a frequent topic at medical conferences such as the European Association for the Study of Diabetes annual meeting.

Category:Antidiabetic drugs Category:Merck & Co. brands